Health Canada Approves AbbVie’s Skyrizi for Pediatric Plaque Psoriasis

PUBT · 2d ago
Health Canada Approves AbbVie’s Skyrizi for Pediatric Plaque Psoriasis
  • Health Canada approved AbbVie's Skyrizi for moderate-to-severe plaque psoriasis in children ages 6 to under 18.
  • Eligible patients must be candidates for systemic therapy or phototherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202610200801CANADANWCANADAPF_C9035) on October 20, 2026, and is solely responsible for the information contained therein.